Emmenegger U - Search Results

1

Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.

Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Wong NS, et al. Among authors: emmenegger u. J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21. J Clin Oncol. 2010. PMID: 20026801 Clinical Trial.

2

A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.

Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. Emmenegger U, et al. Cancer Res. 2004 Jun 1;64(11):3994-4000. doi: 10.1158/0008-5472.CAN-04-0580. Cancer Res. 2004. PMID: 15173013

3

Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.

Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS. Bocci G, et al. Among authors: emmenegger u. Cancer Res. 2004 Sep 15;64(18):6616-25. doi: 10.1158/0008-5472.CAN-04-0401. Cancer Res. 2004. PMID: 15374976

4

Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.

Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M. Bocci G, et al. Among authors: emmenegger u. Ann Oncol. 2005 Aug;16(8):1243-52. doi: 10.1093/annonc/mdi240. Epub 2005 May 19. Ann Oncol. 2005. PMID: 15905308 Free article.

5

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity.

Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Shaked Y, et al. Among authors: emmenegger u. Blood. 2005 Nov 1;106(9):3058-61. doi: 10.1182/blood-2005-04-1422. Epub 2005 Jul 5. Blood. 2005. PMID: 15998832 Free PMC article.

6

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.

Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Shaked Y, et al. Among authors: emmenegger u. Cancer Res. 2005 Aug 15;65(16):7045-51. doi: 10.1158/0008-5472.CAN-05-0765. Cancer Res. 2005. PMID: 16103050

7

Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy.

Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. Yap R, et al. Among authors: emmenegger u. Clin Cancer Res. 2005 Sep 15;11(18):6678-85. doi: 10.1158/1078-0432.CCR-05-0621. Clin Cancer Res. 2005. PMID: 16166447

8

Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy.

Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Munoz R, et al. Among authors: emmenegger u. Breast. 2005 Dec;14(6):466-79. doi: 10.1016/j.breast.2005.08.026. Epub 2005 Sep 30. Breast. 2005. PMID: 16199161 Review.

9

Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents.

Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y, Kerbel RS. Francia G, et al. Among authors: emmenegger u. Mol Cancer Ther. 2005 Oct;4(10):1484-94. doi: 10.1158/1535-7163.MCT-04-0214. Mol Cancer Ther. 2005. PMID: 16227397

10

A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs.

Emmenegger U, Kerbel RS. Emmenegger U, et al. Clin Cancer Res. 2005 Nov 1;11(21):7589-92. doi: 10.1158/1078-0432.CCR-05-1387. Clin Cancer Res. 2005. PMID: 16278375 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

127 results

Search Page

Filters